Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+/HER-2 breast cancer patients treated with CDK4/6 inhibitors
Elevated baseline NLR is associated with an increased risk of severe neutropenia and shorter progression-free survival in patients treated with CDK4/6 inhibitors. These findings highlight a potential link between systemic inflammation and treatment outcomes, suggesting that NLR may be a valuable predictive biomarker in this setting.
Authors
- Aziz Darawshe
- Sameer Sharif (ORCID: https://orcid.org/0000-0002-3346-0308)
- Gil Bar‐Sela (ORCID: https://orcid.org/0000-0001-6579-1841)
- Omar Badran (ORCID: https://orcid.org/0000-0001-6712-0291)
- Samih Yosef
Institutions
- Technion – Israel Institute of Technology (IL)
- Emek Medical Center (IL)
Publication Details
- Journal
- The Breast
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1016/j.breast.2025.104568
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04